BI Asset Management Fondsmaeglerselskab A S Sells 27,442 Shares of Elevance Health, Inc. $ELV

BI Asset Management Fondsmaeglerselskab A S cut its stake in Elevance Health, Inc. (NYSE:ELV) by 18.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 117,966 shares of the company’s stock after selling 27,442 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Elevance Health were worth $38,749,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Rossby Financial LCC raised its stake in shares of Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after buying an additional 44 shares during the last quarter. ORG Partners LLC increased its stake in Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after purchasing an additional 59 shares in the last quarter. Dorato Capital Management bought a new stake in Elevance Health in the fourth quarter valued at approximately $41,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Elevance Health in the fourth quarter valued at approximately $38,000. Finally, Flagship Harbor Advisors LLC bought a new stake in Elevance Health in the fourth quarter valued at approximately $44,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Stock Performance

Shares of ELV stock opened at $415.88 on Friday. The stock has a market cap of $90.31 billion, a P/E ratio of 17.69, a P/E/G ratio of 2.32 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a fifty day moving average price of $354.74 and a two-hundred day moving average price of $341.76. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $416.56.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter last year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 26.94 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ELV shares. Bank of America upped their target price on shares of Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research note on Thursday. Robert W. Baird upped their price target on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Sanford C. Bernstein upped their price target on shares of Elevance Health from $384.00 to $424.00 and gave the company an “outperform” rating in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and increased their target price for the stock from $363.00 to $498.00 in a report on Wednesday, May 20th. Finally, Mizuho increased their target price on shares of Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and an average target price of $411.11.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.